Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Drug: cisplatinDrug: etoposideProcedure: conventional surgeryRadiation: low-LET cobalt-60 gamma ray therapy
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 116
- Registration Number
- NCT00002642
- Locations
- 🇺🇸
Vanderbilt Cancer Center, Nashville, Tennessee, United States
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱Clinica Alemana, Santiago, Chile
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
- Conditions
- NeutropeniaLymphoma
- Interventions
- Biological: filgrastimBiological: pegfilgrastimDrug: cisplatinDrug: cytarabineDrug: etoposideDrug: methylprednisolone
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 60
- Registration Number
- NCT00004192
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 147
- Registration Number
- NCT00005613
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: cytarabineDrug: dexamethasoneDrug: etoposideDrug: idarubicinDrug: ifosfamideDrug: leucovorin calciumDrug: mesnaDrug: pegaspargaseDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapyDrug: Methotrexate
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Kaplan Cancer Center, New York, New York, United States
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
- Conditions
- LymphomaMultiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: bleomycin sulfateBiological: recombinant interferon alfaDrug: cyclophosphamideDrug: cytarabineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: methotrexateDrug: prednisoneDrug: vincristine sulfateProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 20
- Registration Number
- NCT00002657
- Locations
- 🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸CCOP - Dayton, Kettering, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT00003996
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
🇺🇸CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 36
- Registration Number
- NCT00003860
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg, Strasbourg, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00002785
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mesnaDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT00002740
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.